OTC:NXNT
Nexscient, Inc.
A pre-revenue biotech firm leveraging AI-driven drug discovery to target neurodegenerative diseases like Alzheimer's and Parkinson's while managing significant financial deficits.
Key Metrics
Investment Thesis
Bull Case
Investors might consider the stock for its potential to revolutionize neurodegenerative drug discovery through AI, offering an early entry point into a high-growth biotech sector before commercialization.
Bear Case
The stock carries extreme risk due to zero revenue, negative cash flow from operations, and a significant retained earnings deficit that threatens solvency without major capital raises.
About Nexscient, Inc.
Nexscient Inc. is a clinical-stage biotechnology company focused on developing novel small molecules for neurological disorders, operating within the global pharmaceutical and healthcare sectors.
Analysis
Management Discussion
Financial performance shows a substantial net loss of -$529,704 driven by high general and administrative expenses of $390k and interest costs of $41k, resulting in a total equity deficit.
Industry Overview
The global neurodegenerative disease market is vast but highly competitive, requiring substantial R&D investment and long development timelines before any commercial returns are realized.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| R&D | $205.3K | $97.4K |
| G&A | $732.3K | $390.7K |
| D&A | — | $20.3K |
| Non-Operating Income | $0 | $0 |
| Interest Expense | — | $41.7K |
| Continuing Ops | $937.6K | $-529.7K |
| Discontinued Ops | $0 | $0 |
| Net Income | $937.6K | $-529.7K |
| Minority Interest | $0 | $0 |
| Net to Common | $937.6K | $-529.7K |
| Metric | 2024 | 2025 |
|---|---|---|
| Current Assets | $99.8K | $160.3K |
| Cash & Equivalents | $75.8K | $100.5K |
| Other Current Assets | $24.0K | $59.8K |
| Long-Term Assets | $24.6K | $141.4K |
| Operating Leases | $24.6K | $6.4K |
| Other LT Assets | $0 | $135.0K |
| Total Assets | $124.4K | $301.6K |
| Current Liabilities | $36.2K | $64.9K |
| Accounts Payable | $18.0K | $15.0K |
| Current Leases | $18.2K | $6.4K |
| Other Current Liab | $0 | $43.5K |
| Long-Term Liabilities | $6.4K | $501.4K |
| Total Liabilities | $42.6K | $566.3K |
| Shareholders' Equity | $81.8K | $-264.6K |
| Paid-In Capital | $1.1M | $1.3M |
| Retained Earnings | $-1.0M | $-1.6M |
| Total L&E | $124.4K | $301.6K |
| Metric | 2024 | 2025 |
|---|---|---|
| Net Income (CFO) | $937.6K | $-529.7K |
| Non-Cash Adjustments | $-1.6M | $124.9K |
| Working Capital Changes | $-10.9K | $-3.0K |
| Cash from Operations | $-645.5K | $-407.8K |
| Cash from Investing | $0 | $480.0K |
| Cash from Financing | $518.8K | $-47.5K |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-126.7K | $24.7K |
| Beginning Cash | $202.5K | $75.8K |
| Ending Cash | $75.8K | $100.5K |
Frequently Asked Questions
How does Nexscient, Inc. make money?
The company currently operates primarily through its proprietary drug discovery pipeline targeting neurological conditions, with no distinct commercial revenue streams as gross profit is zero.
What are the main risks for NXNT?
The company faces severe financial distress with a net deficit of $1.6M, negative cash flow from operations of -$407k, and no revenue generation.
What is NXNT's competitive advantage?
Nexscient utilizes proprietary AI technology to identify new molecular targets for neurodegenerative diseases, reducing traditional R&D timelines and costs.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.